Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for a Nonopioid Analgesic Candidate in Acute Postoperative Pain

The most common error in an IND annual report is not in its content but in its clock: the deadline runs from the anniversary of the date the IND went into effect, not from a marketing approval or a recent protocol amendment. This article prepares the regulatory operations components of the first annual report for a hypothetical open IND for an oral nonopioid analgesic candidate studied in acute postoperative pain after unilateral total knee arthroplasty. It accounts for a completed Phase 1 study (24 entered) and an ongoing Phase 2 study (36 of 120 entered), tabulates demographics, maps every required element to Module 1.13 of the eCTD, completes Form FDA 1571 as an academic specimen, drafts a cover letter, and sets out a timeline to an April 30, 2027 deadline. It explains why zero IND safety reports does not mean zero serious events and how the DSUR alternative would change the package.Keywords: IND annual report; 21 C.F.R. 312.33; eCTD Module 1.13; regulatory operations; Form FDA 1571; submission lifecycle

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24419717
Primary Topic
Healthcare Regulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for a Nonopioid Analgesic Candidate in Acute Postoperative Pain

Peivand Pirouzi, Perpetua Ulofu, Uchechukwu Veronica Ikechukwu, Yemurayi Hungwe et al.
Zenodo (CERN European Organization for Nuclear Research)
Healthcare Regulation
article

Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for a Nonopioid Analgesic Candidate in Acute Postoperative Pain

Peivand Pirouzi, Perpetua Ulofu, Uchechukwu Veronica Ikechukwu, Yemurayi Hungwe, Precious Chinenye Sunday
article en

Abstract

The most common error in an IND annual report is not in its content but in its clock: the deadline runs from the anniversary of the date the IND went into effect, not from a marketing approval or a recent protocol amendment. This article prepares the regulatory operations components of the first annual report for a hypothetical open IND for an oral nonopioid analgesic candidate studied in acute postoperative pain after unilateral total knee arthroplasty. It accounts for a completed Phase 1 study (24 entered) and an ongoing Phase 2 study (36 of 120 entered), tabulates demographics, maps every required element to Module 1.13 of the eCTD, completes Form FDA 1571 as an academic specimen, drafts a cover letter, and sets out a timeline to an April 30, 2027 deadline. It explains why zero IND safety reports does not mean zero serious events and how the DSUR alternative would change the package.Keywords: IND annual report; 21 C.F.R. 312.33; eCTD Module 1.13; regulatory operations; Form FDA 1571; submission lifecycle

Zenodo (CERN European Organization for Nuclear Research)
Northeastern University (US)
Healthcare Regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon